

## Summary

**Bevacizumab and tocotrienol in recurrent ovarian cancer. A marker based phase II trial (BeTo-Ovar)**  
**EudraCT no.: 2019-000618-13**

The protocol had included 20 patients over a period of 5 years. The very low enrolment rate indicated that the patient population was not large enough to continue with inclusion of the initially planned 60 patients. Enrollment was therefore stopped as per 1 June 2024.

The rate of side effects was reasonable. Three patients experienced treatment related toxicity and subsequent treatment discontinuation. 17 patients experienced progressive disease. Progression free survival was 3 months in this heavily pretreated population of women with ovarian cancer. Analysis of baseline HOXA9 methylated ctDNA showed a trend for improved survival among patients with a level below the median value (p-value= 0.22).

The results of the study will be presented as an abstract at a conference and submitted for publication in a peer-reviewed paper.

21 / 3 - 25 

Torben Frøstrup Hansen  
Professor, MD, PhD, DMSc  
Vejle Hospital, University Hospital of Southern Denmark